📊 SGMO Key Takeaways
Is Sangamo Therapeutics, Inc. (SGMO) a Good Investment?
Sangamo faces an acute solvency crisis with negative stockholders' equity of -$14.3M, current ratio of 0.84x, and annual operating cash burn of -$97.2M against only $20.9M in cash reserves—providing approximately 2.6 months of runway. Revenue declined 31.6% YoY while operating losses reached -$121.2M, indicating fundamental business deterioration despite marginal improvements in loss rates.
Why Buy Sangamo Therapeutics, Inc. Stock? SGMO Key Strengths
- Net loss magnitude improving 25.5% YoY, indicating expense management efforts
- Diluted EPS improving 10.2% YoY showing per-share metrics stabilizing
- Maintains $20.9M cash position providing short-term operational flexibility
SGMO Stock Risks: Sangamo Therapeutics, Inc. Investment Risks
- Negative stockholders' equity of -$14.3M indicates technical insolvency on book value basis
- Current ratio of 0.84x signals acute liquidity crisis unable to cover near-term obligations
- Annual cash burn of $97.2M against $21M cash reserves creates existential runway crisis requiring immediate capital raise or bankruptcy
- Revenue declined 31.6% YoY indicating loss of commercial traction
- Operating margin of -306.5% demonstrates business model severely underwater
Key Metrics to Watch
- Quarterly operating cash burn and remaining cash runway
- Capital raise announcements or debt restructuring events
- Clinical trial milestones and program advancement status
- Year-over-year revenue stabilization or positive inflection
- Operating expense reduction and cash burn improvement initiatives
Sangamo Therapeutics, Inc. (SGMO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
SGMO Profit Margin, ROE & Profitability Analysis
SGMO vs Healthcare Sector: How Sangamo Therapeutics, Inc. Compares
How Sangamo Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Sangamo Therapeutics, Inc. Stock Overvalued? SGMO Valuation Analysis 2026
Based on fundamental analysis, Sangamo Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Sangamo Therapeutics, Inc. Balance Sheet: SGMO Debt, Cash & Liquidity
SGMO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Sangamo Therapeutics, Inc.'s revenue has declined by 51% over the 5-year period, indicating business contraction. The most recent EPS of $-0.49 indicates the company is currently unprofitable.
SGMO Revenue Growth, EPS Growth & YoY Performance
SGMO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $581.0K | $10.7M | $0.04 |
| Q2 2025 | $356.0K | -$20.0M | $-0.08 |
| Q1 2025 | $481.0K | -$30.6M | $-0.14 |
| Q3 2024 | $9.4M | $10.7M | $0.04 |
| Q2 2024 | $356.0K | -$36.1M | $-0.18 |
| Q1 2024 | $481.0K | $21.1M | $0.12 |
| Q3 2023 | $9.4M | -$53.2M | $-0.34 |
| Q2 2023 | $6.8M | -$43.2M | $-0.29 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Sangamo Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
SGMO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Sangamo Therapeutics, Inc. (CIK: 0001001233)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 3, 2026 | 4 | xslF345X06/form4-04032026_040403.xml | View → |
| Apr 3, 2026 | 4 | xslF345X06/form4-04032026_040411.xml | View → |
| Apr 3, 2026 | 4 | xslF345X06/form4-04032026_040407.xml | View → |
| Apr 3, 2026 | 4 | xslF345X06/form4-04032026_040401.xml | View → |
| Apr 3, 2026 | 4 | xslF345X06/form4-04032026_040405.xml | View → |
❓ Frequently Asked Questions about SGMO
What is the AI rating for SGMO?
Sangamo Therapeutics, Inc. (SGMO) has an AI rating of STRONG SELL with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SGMO's key strengths?
Claude: Net loss magnitude improving 25.5% YoY, indicating expense management efforts. Diluted EPS improving 10.2% YoY showing per-share metrics stabilizing.
What are the risks of investing in SGMO?
Claude: Negative stockholders' equity of -$14.3M indicates technical insolvency on book value basis. Current ratio of 0.84x signals acute liquidity crisis unable to cover near-term obligations.
What is SGMO's revenue and growth?
Sangamo Therapeutics, Inc. reported revenue of $39.6M.
Does SGMO pay dividends?
Sangamo Therapeutics, Inc. does not currently pay dividends.
Where can I find SGMO SEC filings?
Official SEC filings for Sangamo Therapeutics, Inc. (CIK: 0001001233) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SGMO's EPS?
Sangamo Therapeutics, Inc. has a diluted EPS of $-0.44.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SGMO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Sangamo Therapeutics, Inc. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SGMO stock overvalued or undervalued?
Valuation metrics for SGMO: ROE of N/A (sector avg: 15%), net margin of -310.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SGMO stock in 2026?
Our dual AI analysis gives Sangamo Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SGMO's free cash flow?
Sangamo Therapeutics, Inc.'s operating cash flow is $-97.2M, with capital expenditures of $102.0K. FCF margin is -246.0%.
How does SGMO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -310.8% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.84 (avg: 2).